Announcements
Radiopharm Theranostics
ASX Announcements
Stay fully informed with all investment-related announcements from Radiopharm Theranostics lodged with the ASX, including financial results, clinical trial updates, and corporate governance.
Recent News
Cancer Research Milestones and 2025 Roadmap
Cancer Research Milestones and 2025 Roadmap Radiopharm Theranostics (ASX:RAD) is dedicated to developing innovative radiopharmaceutical products for both diagnostic and therapeutic applications, addressing high unmet medical needs. In 2024, the company made significant strides in its cancer research. In this
Categories
Tags
Archives
Archives
RSS
- Our Most Important Update of the Year: FDA Removes “Invisible” Dose Ceiling for RLT, Opening a New Era of RLT Innovation; Reit. Buy on CATX, LNTH, RADX
- Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for 161Tb-KLK3-mAb Phase I Clinical Trial in Australia
- RAD Presentation June 2025
- Notice Under Section 708A
- Application for quotation of securities – RAD
- RAD Granted US FDA Fast Track for RAD101 Metastases Imaging
